BASELINE WHOLE BRAIN VOLUME AND DISABILITY PROGRESSION IN OZANIMOD-TREATED PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

Authors
Category Primary study
Conference53 Annual Conference of the Italian Society of Neurology
Year 2023
This article has no abstract
Epistemonikos ID: 0b2ddc4fa41640bbc7e5011062c3c0dc366fd0f7
First added on: Mar 21, 2026